Navigation Links
PATH Malaria Vaccine Initiative and Crucell to test new malaria vaccine approach
Date:7/28/2009

LEIDEN, The Netherlands, July 29, 2009 The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), and Dutch biopharmaceutical company Crucell N.V. today announced a collaboration to accelerate development of a promising type of malaria vaccine. Through funding from the USAID MVDP, the partners will conduct studies to determine the effectiveness of Crucell's novel prime-boost vaccine approach against the malaria parasite, Plasmodium falciparum. This approach uses Crucell's proprietary recombinant adenoviruses (a type of virus associated with the common cold and other mild respiratory infections) to deliver a malaria antigen to the immune system.

Dr. Jaap Goudsmit, Chief Scientific Officer at Crucell, commented, "This agreement is a strong validation of Crucell's malaria vaccine approach. We are excited to have MVI as our partner and to have the support of USAID. The fact that MVI is backing our program testifies to the importance of our efforts to further progress the development of Crucell's malaria vaccine."

For MVI, this partnership adds to its existing portfolio a vaccine approach with the potential to elicit a more comprehensive immune response than has been seen to date from the circumsporozoite protein (CSP), the only antigen that has proven to be protective against malaria in controlled challenge studies and field studies. Using Crucell's AdVac technology with two different vectorsthe adenovirus serotypes Ad35 and Ad26 as delivery mechanisms, this approach seeks to elicit a protective immune response obtained from delivering the CSP. The safety, immunogenicity and efficacy data from these studies will further advance the research forward development of a safe and highly efficacious malaria vaccine.

"Adenoviruses are one of the most potent vaccine delivery systems tested to date in humans. We are excited about the potential of C
'/>"/>

Contact: Preeti Singh
psingh@burnesscommunications.com
301-652-1558 x5722
Burness Communications
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Counterfeit antimalarial drug discovered in Ghana
2. New global subsidy for malaria medicines must ensure quality of care
3. Miles To End Malaria Program Gets an Extra Burst of Speed From American Le Mans Series Founder Don Panoz
4. Global Fund Increases AIDS, Tuberculosis and Malaria Prevention and Treatment Measures by 30-50% Over One Year
5. Marathon and Partners Announce Dramatic Results of Malaria Control Project on Bioko Island in Equatorial Guinea
6. Deploying the Power of Music to Save Lives West Africas Most Beloved Singer Raises His Voice to End Malaria
7. House Subcommittee Markup Leaves Global Fund to Fight AIDS, TB, and Malaria in Crisis
8. Washington, DC Community Leaders Commit to Send 10,000 Anti-Malarial Bed Nets to Refugees in Africa
9. Prospero Group (PRPG) and Fincor (FINC) Made a Share Transfer and Enter the Market with ACTRx a New Malaria and Dengue Fever Treatment
10. Simple blood test proves powerful ally in the fight against malaria
11. UN Foundation to Help Protect More than a Million Refugees from Malaria in Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2
... researchers have discovered a new method to test for ... for chromosomal abnormalities are currently done through amniocentesis and ... scientists have been able to isolate single cells of ... woman with the help of a cervical swab. This ...
... delay your chances of getting treated// for cancer early. ... of Cancer, valuable time is lost when cancer patients goes ... suspected prostate cancer might be diagnosed three times later than ... gets treated for cancer. The average time for the diagnosis ...
... of inability to read in dyslexic children is// not ... thought in recent years. Instead, the dyslexic children may ... ,Dyslexia is one type of specific learning disability. ... verbal skills, abstract reasoning, hand-eye coordination, concentration, perception, memory ...
... School of Medicine have successfully discovered how the body’s ... like leprosy in some cases but not in others. ... system often fights with the infections in the initial ... they are unable to control the bug that it ...
... suffering from chronic lower back pain for more than a ... is done when no other treatment seems to bring them ... British Medical Journal reveled that in the long run this ... do not have enough finance to sustain a long-term medical ...
... sleep apnea syndrome affects a lot of people who ... top of having a difficult night, these people may ... ,Obstructive sleep apnea syndrome (OSAS), also known as ... heart problems, stroke, obesity, breathing problems, sexual dysfunction and ...
Cached Medicine News:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... Combination Clinical Trials ... SOUTH SAN FRANCISCO, Calif., June 16 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... the company,s lead drug candidate, voreloxin (formerly,SNS-595), including updated results ... single agent in relapsed or refractory patients with acute,myeloid leukemia ...
... Requip XL Improved Symptoms in Patients Not Optimally ... "Off" Time by Nearly Two Hours Per Day, ... (NYSE: GSK ) today announced the approval ... for the treatment,of the signs and symptoms of ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 6U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 2U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 3U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 4U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: